Clinical trial
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With…
NCT00281632 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00281632 |
|---|---|
| Title | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer |
| Official title | This Study is a Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer |
| Intervention type | Drug |
| Interventions | GW786034 |
| Enrollment | 35 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Oct 1, 2010 |
| First posted | Jan 25, 2006 |
| Last update posted | Sep 17, 2018 |
| Countries | Australia, Singapore, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: